PALO ALTO, Calif., Oct. 24 /PRNewswire/ -- Vivo Ventures, a venture capital firm specializing in life science investments, today announced that James Huang will join the firm as an Executive in Residence. With his extensive business development and operating experience, Mr. Huang will work with Vivo's portfolio companies while enhancing the firm's presence in Asia.
"We are excited about James coming on board and what he will be able to bring to Vivo," said Frank Kung, Managing Partner of Vivo Ventures. "His extensive relationships throughout the pharmaceutical industry, his impressive track record in closing multiple business development partnerships, and his experience in building companies make him a valuable asset to our team and our portfolio companies."
"Vivo Ventures is one of the best recognized life sciences venture firms in the U.S. and in Asia. I am very enthused about the opportunity to contribute to the success of Vivo's existing and future portfolio companies," commented James Huang.
About James Huang
With 20 years of experience in the pharmaceutical industry, James joins Vivo from Anesiva, where he has served as president since September 2005. Previously, he had served as Anesiva's senior vice president of business development and commercial operations.
He joined Anesiva from Tularik Inc., where he held the position of vice
president of business development and commercial operations and led the
development and negotiation of commercial and scientific collaborations,
alliances, and licensing agreements. Among the most notable include: a
collaboration with Medarex to develop and commercialize human therapeutic
antibodies; a collaboration with Sankyo to jointly discover and develop
human therapeutics related to orphan G-protein coupled receptors (GPCRs);
as well as other technology collaborations and corporate development
acquisitions. Mr. Huang also guided strategic planning and execution for
Tularik's marketing progr
|SOURCE Vivo Ventures|
Copyright©2007 PR Newswire.
All rights reserved